Roche recently signed a definitive share purchase agreement to acquire 100 percent of the outstanding shares of TIB Molbiol Group to enhance its molecular diagnostic solutions portfolio.
The...
Thermo Fisher Scientific recently launched a new mass spectrometry (MS) portfolio to advance quantitative analysis.
The Thermo Scientific TSQ Plus triple quadrupole MS portfolio increases...
Sanofi recently entered into a $1.9 billion pharma acquisition deal with Kadmon Holdings to strengthen the growth of its transplant business.
Under the terms of the agreement, Sanofi will continue to...
Pfizer recently initiated a Phase 3 clinical trial evaluating the efficacy, immunogenicity, and safety of a single dose of its respiratory syncytial virus (RSV) vaccine candidate in adults.
The...
Medidata and Labcorp Drug Development recently entered into an agreement to expand decentralized clinical trial capabilities and digital biomarker discovery.
The companies will leverage Medidata...
Moderna and the Institute for Life Changing Medicines (ILCM) recently collaborated to develop a new mRNA therapeutic (mRNA-3351) for ultra-rare disease, Crigler-Najjar Syndrome Type 1...
Eli Lilly and Company recently announced that its prescription medicine, Jardiance, elicited a 21-percent relative risk reduction in death or hospitalization for heart failure patients compared to...
FDA recently approved Johnson & Johnson’s long-acting atypical antipsychotic, Invega Hafyera, the first and only twice yearly injectable to treat schizophrenia in adults.
Providers...
Novartis and NHS England recently reached a commercial agreement to enable broad access to Novartis’ RNA therapy, Leqvio, which helps lower LDL cholesterol (LDL-C) in eligible patients with...
Thermo Fisher Scientific and AstraZeneca recently entered into a global, multiyear partnership to co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) for targeted...
Eli Lilly and Company recently entered into a multi-year research collaboration and licensing agreement with Lycia Therapeutics to discover, deliver, and commercialize novel targeted drug...
FDA recently approved the MicroTransponder Vivistim Paired VNS System (Vivistim System) to treat moderate to severe upper extremity motor deficits associated with chronic ischemic...
Novartis recently announced that the Phase 3 clinical trial investigating its aggressive B-cell-non-Hodgkin lymphoma (NHL) treatment, Kymriah, did not meet its primary endpoint of event-free survival...
Digital therapeutics present potential solutions for chronic diseases management, ranging from Alzheimer’s disease, type 2 diabetes, congestive heart failure, and cancer. The same technologies...
Johnson and Johnson recently announced that FDA approved an expanded peripheral artery disease (PAD) indication for its Xarelto vascular dose.
The indication will now include patients following recent...
Bristol Myers Squibb recently announced that FDA accepted a supplemental biologics license application for its Acute Graft Versus Host Disease (aGvHD) therapy, Orencia.
Orencia is intended to...
Pfizer recently entered into a $2.26-billion pharma acquisition deal with clinical-stage immuno-oncology company, Trillium, to strengthen its next-generation, investigational immuno-therapeutics...
FDA recently granted accelerated approval to GSK’s PD-1 blocking antibody drug, Jemperli, for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid...
GoodRx and Boehringer Ingelheim recently collaborated to increase affordable drug access for patients with type 2 diabetes or chronic obstructive pulmonary disease (COPD).
Under the...
